No Data
Why Is Cytokinetics, Incorporated (CYTK) Among the Worst Performing Biotech Stocks in 2024?
Mizuho Maintains Outperform on Cytokinetics, Raises Price Target to $103
Express News | Cytokinetics Inc : Mizuho Raises Target Price to $103 From $99
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
Unusual Options Activity: MET, CNH and Others Attract Market Bets, MET V/OI Ratio Reaches 318.2
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $70 to $120